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ABSTRACT
Autoimmune hypophysitis is an autoimmune inflammation of the pituitary gland. It may result in hypopituitarism depending upon 
the part of pituitary affected. Here, we report the case of autoimmune hypophysitis in a 30-year-old male who was admitted with 
complaints of generalised swelling for one month and fever and cough for one week. The patient’s Thyroid-stimulating hormone 
(TSH) was more than 139, anti-thyroid peroxidase antibody (anti-TPO) was more than 1000 and serum sodium was 107 and a tiny 
streak of tissue along the periphery with an empty sella as seen on MRI. The patient was given tablet Levothyroxine 100 microgram, 
Telmisartan 40 mg and Hydrocortisone 10mg twice daily. With medications, the patient improved and was discharged.
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Autoimmune hypophysitis is a rare disorder that may mimic pituitary adenoma and occurs mostly in women in the peripartum period. Primary hypophysitis is a 
rare disease. The incidence is estimated to be ~1 in 9 million/
year [1] and only a few cases have been reported inmen [2]. 
The symptoms depend on the part of the pituitary affected. 
Lymphocytic adenohypophysitis (LAH) occurs when the anterior 
cells are affected by autoimmune inflammation resulting in either 
hypothyroidism (if TSH producing cells are damaged) or adrenal 
insufficiency (if ACTH producing cells are affected). Lymphocytic 
infundibulo neurohypophysitis (LINH) occurs when the posterior 
pituitary is affected. It is estimated that typically, it takes 12-
40 years for autoimmune destruction to present symptoms. 
Approximately, 80% of patients with pituitary antibodies also 
have antibodies to thyroid gland or its hormone [3] and 20% of 
autoimmune thyroid patients have pituitary antibodies [4].
CASE REPORT
A 30-year-old unmarried male presented with complaints of 
generalised swelling for one month, with fever and cough for one 
week. There was a history of lethargy and obstructive sleep apnea 
(as noticed by family members). There was a past history of 
recurrent jaundice (for 2-3 times) 10-12 years back. The patient 
was non-diabetic and the history was not suggestive of any intake 
of drugs or immunosuppressive agents. There was no history of 
trauma or any intracranial irradiation. 
General examination revealed blood pressure of 170/110 
mm Hg and the rest of the vitals were stable. Pedal edema was 
present with Body Mass Index (BMI) of 32.5. The laboratory 
investigations were shown in Table 1.
Hyponatremia was corrected by giving 3% sodium chloride 
solution intravenously along with oral sodium chloride 
supplementation. For hypothyroidism and hypertension, tablet 
Levothyroxine 100 microgram and tablet Telmisartan 40mg were 
given to the patient respectively. The patient was given Tablet 
Hydrocortisone 10mg twice daily. After therapy, patient improved 
and was discharged. On follow-up after one and a half month, 
the patient’s blood pressure was 130/90 mm of Hg, thyroid-
stimulating hormone was 35 microIU/L and serum sodium was 
135 mEq/l. The patient resumes his normal duty.
DISCUSSION
Autoimmune hypophysitis is a potential cause of secondary 
empty sella considering that pituitary gland, following the 
Table 1: Laboratory investigations of the patient.
S. sodium 107mEq/l
Random plasma glucose (RPG) 114 mg/dl
T3 < 0.40mmol/L
T4 <6.00mmol/L
TSH >139microIU/L
Anti-thyroid peroxidase 
antibody
>1000IU/L
Creatinine 0.9
Haemoglobin 9.4
Magnetic resonance Imaging  
Brain
Sella shows CSF collection with 
tiny streak of tissue 
along the periphery. Empty sella
Antinuclear antibody Negative (1:80 dilution)
Haemoglobin typing Adult Haemoglobin with high A2
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initial increase in size, gradually becomes atrophic and fibrotic 
[5]. Histopathologically, there are five forms of hypophysitis: 
lymphocytic granulomatous, xanthomatous, IgG4 related and 
necrotizing. Lymphocytic hypophysitis is the most common form. 
In the acute phase, it may present as sella or parasellar mass and 
in the chronic phase, autoimmune hypophysitis may present as 
an empty sella syndrome. The clinical features of empty sella are 
headache, hypertension, visual symptoms and hypopituitarism 
but most of the time it may be asymptomatic.
Biopsy and the histological examination is the only means 
of accurate diagnosis as no autoantigen has been discovered [6]. 
However, a biopsy of the pituitary is not easily performed with 
safety as it sits under the brain. Tests for normal pituitary gland 
hormone production tend to be expensive and some cases are 
difficult to administer. In addition, certain hormone levels vary 
largely throughout the day and in response to metabolic factors 
making abnormal level difficult to calibrate [7-12]. Furthermore, 
anti-pituitary antibodies can be expected to be positive in 18% of 
women during the postpartum period [13].
An autoimmune etiology for lymphocytic hypophysitis 
was suggested by the presence of pituitary antibodies that may 
recognize α-enolase, Growth hormone, the pituitary gland-
specific factors 1a and 2 (PGSF1a and PGSF2), regulatory 
prohormone-processing enzymes commonly produced in the 
pituitary gland (PC1/3, PC2, CPE and 7B2), secretogranin 
II, chromosome 14 open reading frame 166 (C14orf166), the 
corticotroph-specific transcription factor TPIT and chorionic 
somatomammotrophin (HCS) [14-22]. However, the pathogenic 
role of these autoantibodies is unclear and they are not specific to 
hypophysitis. For example, pituitary antibodies were identified 
by indirect immunofluorescence in ~45% of patients with biopsy-
proven hypophysitis, but were also found in the serum of patients 
with isolated central diabetes insipidus (35%), germinomas (33%), 
isolated anterior hormone deficiencies (29%), prolactinomas 
(27%), Rathke’s cleft cysts (25%), craniopharyngiomas (17%) 
nonfunctioning pituitary tumors (13%), GH-secreting pituitary 
tumors (12%) and healthy subjects (5%) [23,24]. They can also 
be found in patients with autoimmune endocrine disorders, 
especially Hashimoto thyroiditis [24]. 
In the above context, Hashimoto’s thyroiditis with incidental 
finding of empty sella on MRI of the brain may be a differential 
diagnosis. In the presence of MRI brain suggestive of empty sella 
with a tiny streak of tissue along the periphery in the sella, the 
possibility of autoimmune hypophysitis cannot be ruled out as 
there is no confirmatory test available till date.
Conservative management is recommended for primary 
hypophysitis unless symptoms are severe and progressive. The 
only exception to this rule is IgG4-related hypophysitis that – like 
other manifestations of the disease – should be promptly treated 
to revert symptoms and prevent fibrosis [25]. The mainstay of 
treatment is glucocorticoid, which often cause remission of 
symptoms within a few weeks. A typical starting dose is prednisone 
30-40 mg/day (or equivalent), which should be continued for 
2-4 weeks, and then tapered gradually over 2-6 months [26]. 
Hormone deficiencies improved with glucocorticoids only in 
15% of patients, while they remained stable or worsened in 70% 
and 15% of cases, respectively [27]. In glucocorticoid-resistant 
cases and when high-dose glucocorticoids cause unacceptable 
side effects, immunosuppressive drugs such as azathioprine, 
methotrexate, and cyclosporine A have been used successfully 
[28].Surgery should be considered only in cases with serious 
and progressive deficits of the visual field, visual acuity, or nerve 
paralysis not responsive to medical treatment.
CONCLUSION
Although autoimmune hypophysitis is a rare disorder, it is being 
increasingly recognised.In the absence of a surgical emergency, 
such as impending loss of vision, medical management combined 
with sequential MRI is preferable. Diagnosis and management 
will be further improved when a robust immunological diagnostic 
test becomes available.
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